CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. AstraZeneca and Ionis add an EU green light to ...

The company made a major breakthrough in late 2023 when its first product, CASGEVY, became the first ... particularly with its LYFGENIA (lovotibeglogene autotemcel, or lovo-cel) gene therapy ...

While bluebird priced Lyfgenia at $3.1 million, Vertex priced Casgevy at $2.2 million. But the company struggled to build a market. In November, bluebird said it had just 57 patient starts ...

The FDA approved Lyfgenia and Vertex Pharmaceuticals' (VRTX) Casgevy for the treatment of sickle cell disease in December 2023. Casgevy was co-developed with CRISPR Therapeutics (CRSP).

In December 2023, the FDA approved CASGEVY and LYFGENIA the first cell-based gene therapy for treating sickle cell disease (SCD) in patients aged 12 years and older. In June 2023, Sarepta ...

Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...

But the 2023 FDA approval of Lyfgenia in sickle cell disease did not come with a voucher. That approval was announced concurrent with the regulatory nod for Casgevy, a Vertex Pharmaceuticals gene ...

Its third gene therapy, Lyfgenia (lovotibeglogene autotemcel ... of time in December 2023 on the same day as Vertex/CRISPR’s Casgevy (exagamglogene autotemcel), approved for the same indication.

Casgevy was approved at the same time as a rival treatment, bluebird bio’s Lyfgenia (lovotibeglogene autotemcel). Both treatments were given marketing authorisation for the same condition ...